Nav: Home

Study finds lung transplant patients not given antifungal preventive drugs have higher risk of death

September 23, 2020

ROCHESTER, Minn. -- Antifungal preventive medications reduce mortality risk by half in the first year following lung transplantation, according to Mayo Clinic research involving 667 patients who received lung transplants from 2005 to 2018.

The retrospective study, published in the Annals of the American Thoracic Society, is the largest ever to evaluate the effectiveness of antifungal preventive drugs in lung transplant recipients who are particularly susceptible to invasive fungal infections. These infections are associated with a nearly threefold increase in mortality for lung transplant recipients.

Mayo Clinic researchers used deidentified administrative claims data from OptumLabs Data Warehouse. The study analyzed data for adult patients who underwent single or double lung transplant, or concurrent heart-lung transplant, in the U.S. between Jan. 1, 2005, and Dec. 31, 2018. Of the 667 patients, 385, or 57.8%, received antifungal treatment and 282, or 42.3%, did not. Sixty-five patients died during the study, and all-cause mortality was significantly lower in those patients who received antifungal medications.

"Use of antifungal preventive medications in lung transplant patients is increasingly common, but no studies have established its efficacy," says Kelly Pennington, M.D., the study's first author. "This is the first study to demonstrate a mortality benefit associated with the use of antifungal prophylaxis in lung transplant patients. We still do not know which lung transplant patients receive the most benefit from these medications, and there are other unanswered questions that will require more research." Dr. Pennington is a Mayo Clinic Scholar in the Division of Pulmonary and Critical Care Medicine.

A 2019 Mayo Clinic study found that 90% of U.S. transplant centers routinely prescribe antifungal preventive medications after lung transplant, but no prospective studies have established the benefits of these medications. "In our retrospective study, the risk of death within the first year posttransplant is about twice as high in patients not receiving antifungal preventive treatment, compared with those receiving treatment," says Dr. Pennington.

Itraconazole and voriconazole were the two most common antifungal preventive medications prescribed in the study. Patients who received antifungal drugs had a lower rate of fungal infections than those who did not, though the difference was not statistically significant.

Protracted use of antifungal drugs can have negative health effects, including cardiomyopathy, skin cancer and liver dysfunction. Also, antifungal medications are expensive and can interact with other medications. Therefore, the health care team must monitor anti-fungal medications closely.

"Given the variation in practice among transplant centers, the potential for medication side effects, medication costs and risk of drug interactions, it was imperative to determine whether antifungal preventive medications are beneficial for lung transplant recipients," says Cassie Kennedy, M.D., senior author. "Our finding of a significant reduction in mortality risk among lung transplant recipients who received antifungal medications is consistent with several prior studies in hematologic malignancies and bone marrow transplant patients." Dr. Kennedy is a physician in Mayo Clinic's Division of Pulmonary and Critical Care Medicine. None of the authors has a conflict of interest to disclose. Dr. Kennedy is supported by HNLB1 grant K23 HL128859 from the National Institutes of Health (NIH). Dr. Pennington is supported by Mayo Clinic's Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. Nilay Shah, Ph.D., is supported by grants from the Centers of Medicare & Medicaid Innovation Center, Food and Drug Administration, Agency for Healthcare Research and Quality, NIH's National Heart, Lung and Blood Institute, Medical Devices Innovation Consortium/National Evaluation System for Health Technology, National Science Foundation, and Patient-Centered Outcomes Research Institute.
-end-
About Mayo Clinic

Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news and Mayo Clinic Facts for more information about Mayo.

Mayo Clinic

Related Mortality Articles:

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.
Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.
What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.
COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.
COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.
Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.
Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.
Examining the link between caste and under-five mortality in India
In India, children that belong to disadvantaged castes face a much higher likelihood of not living past their fifth birthday than their counterparts in non-deprived castes.
Mortality rates rising for Gens X and Y too
Declining life expectancies in the US include Gen X and Y Americans, in addition to the older Baby Boomers.
Trust in others predicts mortality in the United States
Do you trust other people? It may prolong your life.
More Mortality News and Mortality Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.